Data

Click on Protocol Number of interest to view study-related documentation or download data files. (DTMC data files are under development.)
Division Sort descending Study Number Title Investigator(s) Release Date
DTMC NIDA-MDS-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence Ann Anderson, M.D. Dec 04, 2014
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D. Aug 01, 2016
DTMC NIDA-CTO-0004 Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline Thomas F. Newton, M.D. Aug 01, 2016
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D. Aug 01, 2016
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., T. John Winhusen, Ph.D. Aug 01, 2016
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CPU-0006 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine Reese Jones, M.D. May 23, 2017
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D. May 23, 2017
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017